Stocks Market

Stocks Market

Laprophan's Amanys Pharma Plans Major Production Shift and $37M Injectable Plant Investment

Laprophan is orchestrating a strategic reorganization of its pharmaceutical operations through its wholly-owned subsidiary Amanys Pharma. The company plans to gradually relocate antibiotic and injectable production from Casablanca to its Aïn El Aouda complex between 2027 and 2029, requiring an investment of 26 million dirhams. This move accompanies a larger industrial expansion featuring a new 374 million dirham injectable manufacturing facility, financed primarily through debt (53%), with operations expected to commence in Q4 2027 and annual capacity reaching 30 million consumer units.

November 12th, 2026
3 min read
By boursenews.ma

Listen to this article

Unlock audio versions of premium articles and more with a Pro subscription.

Laprophan is preparing a comprehensive reorganization of its industrial operations centered around the Amanys Pharma complex in Aïn El Aouda. The pharmaceutical group has announced plans to progressively transfer antibiotic and injectable manufacturing from its historic Casablanca facility to this platform between 2027 and 2029, allocating 26 million dirhams for the transition.

This strategic redeployment supports the capacity expansion at Amanys Pharma, which Laprophan acquired completely in March 2024. The Aïn El Aouda complex, situated on 62,000 square meters of land, houses a beta-lactam antibiotic production unit operational since 1996, alongside a newly constructed sterile injectable plant.

Major Injectable Manufacturing Investment

Unveiled to the press on Wednesday, the new injectable facility represents a 374 million dirham investment, with financing split between 200 million dirhams in debt and 174 million dirhams in equity. The plant is scheduled to begin operations in the fourth quarter of 2027, delivering an annual capacity of 30 million consumer units.

The existing antibiotic unit is also slated for production increases, expanding from the current 15 million consumer units to 25 million by 2027. Combined, both facilities encompass 25,300 square meters of built space.

Extensive Market Authorization Portfolio

Amanys Pharma maintains more than 350 marketing authorizations (AMM) and claims national leadership in beta-lactam antibiotic manufacturing. Its operations extend across intensive care, resuscitation, hematology, and specialized oncology sectors.

The company leverages multiple commercial and industrial agreements with international laboratories. Notably, it handles local antibiotic manufacturing for GlaxoSmithKline (GSK) under an exclusive industrial contract with minimum volume commitments.

Amanys has also secured exclusive distribution and promotion agreements with Amgen Europe for innovative specialties and biomedicines in Morocco, as well as with Natco Pharma for oncology treatments targeting the Moroccan market and francophone sub-Saharan Africa.

Its partnership with Octapharma focuses on blood derivatives and hematology treatments in Morocco, Côte d'Ivoire, and Gabon, accompanied by annual purchase volume commitments.

Export Strategy Through Subsidiaries

Amanys Pharma centralizes exports of all specialties manufactured by Laprophan in Morocco. The company maintains commercial presence across 13 African countries, primarily in West and Central Africa, with a representative office in Côte d'Ivoire.

Two wholly-owned subsidiaries complete this international structure. Amanys Pharma India Private Ltd, based in Pune, handles procurement of active pharmaceutical ingredients and manages subcontracting partnerships in Asia.

Amanys Pharma International FZCO, established in Dubai, conducts trading and distribution activities toward sub-Saharan Africa and the Middle East.

Organizational Structure and IPO Context

Originating from GSK Morocco's operations, Amanys Pharma employed 207 staff members in 2025, including 44 executives. Its board of directors is chaired by Farid Bennis, CEO of Laprophan, while general management is led by Zineb Benjelloun Touimi, former site director at GSK Morocco.

These industrial projects and Amanys' commercial scope represent significant factors in evaluating Laprophan's activities, particularly as the company pursues a 2.22 billion dirham initial public offering, including nearly 1.4 billion dirhams through capital increase.

Discussion (0)